TY - JOUR
T1 - A multifunctional nanostructured platform for localized sustained release of analgesics and antibiotics
AU - Murphy, Matthew B.
AU - Khaled, S. M.
AU - Fan, Dongmei
AU - Yazdi, Iman K.
AU - Sprintz, Michael
AU - Buchanan, Rachel M.
AU - Smid, Christine A.
AU - Weiner, Bradley K.
AU - Ferrari, Mauro
AU - Tasciotti, Ennio
N1 - Funding Information:
This study has been supported by the Defense Advanced Research Projects Agency Fracture Putty Program (DARPA W911NF-09-1-044). The authors would like to thank Lucas Isenhart, Song Kim, and Flor Mendez for their contributions.
PY - 2011/11
Y1 - 2011/11
N2 - The current delivery methods for pain medication, local anesthetics, antibiotics, and steroids present several limitations mainly due to their route of administration, which results in suboptimal pain management, potential systemic toxicity, and subtherapeutic levels which increases the risk of microorganisms developing antibiotic resistance. Our group developed a hybrid material consisting of nanoporous silicon (pSi) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles, loaded with antibiotics and pain relief medications, respectively. The medications were delivered via a bioactive angiogenic gel of platelet-rich plasma (PRP). This system releases both molecules in a sustained and controlled fashion while simultaneously promoting wound healing and vascularization of the surgical site. The resulting advantages include improved medication efficacy at a lower total drug concentration, decreased risk of systemic toxicity, and for antibiotics, decreased risk of developing resistance. The versatile nature of our platform allows for a variety of different drugs, molecules, biological factors to be loaded and released by the gel. Moreover, by tuning the chemical and physical properties of each component, it is possible to tailor the release rate of each biomolecule to its desired therapeutic level. Therapeutic and antimicrobial agents were released at potent daily dosages for up to 7. days by combination of PLGA and pSi particles free or embedded within the PRP gel. When implanted in vivo, the composite gel was vascularized and infiltrated with endogenous cells by 2. weeks while exhibiting no symptoms of inflammation or immune response. This novel technology has the potential to dramatically affect the post-operative management of patients with an immediate improvement in post-operative pain management, decreased PACU and hospital length of stays, with subsequently decreased hospital and surgical costs. Furthermore, this unique and effective drug delivery platform technology may eliminate the need for subsequent treatments, repeat dosing, and dramatically improve patient convenience and patient compliance.
AB - The current delivery methods for pain medication, local anesthetics, antibiotics, and steroids present several limitations mainly due to their route of administration, which results in suboptimal pain management, potential systemic toxicity, and subtherapeutic levels which increases the risk of microorganisms developing antibiotic resistance. Our group developed a hybrid material consisting of nanoporous silicon (pSi) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles, loaded with antibiotics and pain relief medications, respectively. The medications were delivered via a bioactive angiogenic gel of platelet-rich plasma (PRP). This system releases both molecules in a sustained and controlled fashion while simultaneously promoting wound healing and vascularization of the surgical site. The resulting advantages include improved medication efficacy at a lower total drug concentration, decreased risk of systemic toxicity, and for antibiotics, decreased risk of developing resistance. The versatile nature of our platform allows for a variety of different drugs, molecules, biological factors to be loaded and released by the gel. Moreover, by tuning the chemical and physical properties of each component, it is possible to tailor the release rate of each biomolecule to its desired therapeutic level. Therapeutic and antimicrobial agents were released at potent daily dosages for up to 7. days by combination of PLGA and pSi particles free or embedded within the PRP gel. When implanted in vivo, the composite gel was vascularized and infiltrated with endogenous cells by 2. weeks while exhibiting no symptoms of inflammation or immune response. This novel technology has the potential to dramatically affect the post-operative management of patients with an immediate improvement in post-operative pain management, decreased PACU and hospital length of stays, with subsequently decreased hospital and surgical costs. Furthermore, this unique and effective drug delivery platform technology may eliminate the need for subsequent treatments, repeat dosing, and dramatically improve patient convenience and patient compliance.
KW - Controlled release
KW - Drug delivery
KW - Nanomedicine
KW - Platelet-rich plasma
UR - http://www.scopus.com/inward/record.url?scp=83355177380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83355177380&partnerID=8YFLogxK
U2 - 10.1016/j.eujps.2011.08.002
DO - 10.1016/j.eujps.2011.08.002
M3 - Article
AN - SCOPUS:83355177380
SN - 1754-3207
VL - 5
SP - 423
EP - 432
JO - European Journal of Pain Supplements
JF - European Journal of Pain Supplements
IS - 2
ER -